Alcoholverslaving substance dependence
Conditions
Interventions
20 subjects will participate in 2 treatment periods, and will be administered
each of the following treatments:
• Treatment A: 5- hour alcohol-clamp at a level of 0.6 g•L-1 in combination
with match
Sponsors
GlaxoSmithKline
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters significantly outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. 2. Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent. 3. A female subject is eligible to participate if she is of: • Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive). 6. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. 7. Average QTcB or QTcF
Exclusion criteria
Exclusion criteria: 1. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening. 2. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). 3. History or presence of clinically significant cardiac arrhythmias, or other clinically significant cardiac disease. 4. Subjects, who in the investigator's judgement, pose a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behaviour and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 6 months. 5. Significant renal abnormality (from medical history or as indicated by laboratory investigations). Additionally subjects with idiopathic haematuria or proteinuria or conditions such as benign orthostatic proteinuria and benign familial haematuria should be excluded from the study) 6. Subjects with LFT >1.5 ULN 7. Subjects, who in the investigator's judgement, pose a significant homicidal risk or have ever been homicidal. 8. A positive pre-study drug/alcohol screen. 9. A positive test for HIV antibody. 10. History of regular alcohol consumption within 6 months of the study defined as: • an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits. 11. Past history of alcohol dependence or abuse. 12. History of increased sensitivity to the effects of alcohol or violent behaviour/aggression when intoxicated. 13. Inability to adequately perform pharmacodynamic testing during the training session. 14. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). 15. Exposure to more than four new chemical entities within 12 months prior to the first dosing day. 16. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John*s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. 17. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. 18. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. 19. Unwillingness or inability to follow the procedures outlined in the protocol. 20. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. 21. Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or Chinese grapefruit (pomelo), exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacodynamic: • Saccadic eye movements (saccadic reaction time, saccadic peak velocity and saccadic accuracy): to assess sedation. • Smooth pursuit eye movements (percentage of time the eyes are in smooth pursuit of the target): to assess attention and eye movement coordination. • Body sway (antero-posteral sway in mm/2min): to assess body movements in a single plane, providing a measure of postural (in)stability. During sway measurements, subjects will be instructed to keep their eyes closed for two minutes. • Adaptive tracking (average performance %): to assess visuo-motor control and vigilance. • Visual Verbal Learning Test (VVLT) for the assessment of cognition. • Visual Analogue Scale (VAS) for subjective effects of alcohol. • Epworth Sleepiness Scale to assess change in sedation • Bond and Lader VAS for alertness, calmness and contentedness. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Vital signs, 12-lead ECGs, clinical laboratory and AEs Pharmacokinetics: • Breath ethanol (EtOH) concentrations (BrAC) • PK parameters of GSK1144814 (in the presence of blood alcohol): AUC (0-24h), Cmax, Tmax. | — |
Countries
Netherlands
Outcome results
None listed